Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

NeoVasculoStop

Financiado

NATURAL INTRAOCULAR PHOTOACTIVATION OF COMPOUNDS TO FIGHT RETINOPATHIES

Retinopathies constitute an extreme societal and socioeconomic burden that is expected to increase with an aging population and the increased prevalence of diabetes. These diseases, including age-related macular degeneration and p... ver más

28/02/2026

Experimentica Ltd

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

EXPERIMENTICA OY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 6 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-03-28

HORIZON-EIC-2021-PATHFINDEROPEN-01-01: EIC Pathfinder Open 2021 Scope:You should apply to this call if you are looking for support from EIC Pathfinder Open to reali...

I+D

Cerrada hace 3 años

0% 100%

6 Participantes

Experimentica Ltd

1.00M€ | Lider

LC INNOCONSULT INTERNATIONAL

202.91K€ | Participante

EMMES BIOPHARMA GLOBAL S.R.O...

201.26K€ | Participante

VICHEM CHEMIE KUTATO KFT

697.41K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

RTI2018-094071-B-C21 DELIVERY DE EXOSOMAS ARTIFICIALES PARA EL TRATAMIENTO DE ENF... 218K€ Cerrado

PDC2022-133132-I00 MEJORAS EN EL DIAGNOSTICO E INVESTIGACION CLINICA MEDIANTE T... 127K€ Cerrado

RTC-2014-2038-1 Nuevos Tratamientos para enfermedades degenerativas de la re... 228K€ Cerrado

BES-2016-076410 NUEVAS MOLECULAS MULTIDIANA Y TERANOSTICAS PARA EL DIAGNOSTI... 93K€ Cerrado

RTI2018-099597-B-I00 DESARROLLO DE SISTEMAS BIODEGRADABLES INTRAOCULARES DE ANTIV... 109K€ Cerrado

PDC2023-145857-I00 Herramientas diagnósticas, pronósticas y terapéuticas 90K€ Cerrado

Duración del proyecto: 47 meses Fecha Inicio: 2022-03-28
Fecha Fin: 2026-02-28

Líder del proyecto

EXPERIMENTICA OY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Descripción del proyecto Retinopathies constitute an extreme societal and socioeconomic burden that is expected to increase with an aging population and the increased prevalence of diabetes. These diseases, including age-related macular degeneration and proliferative diabetic retinopathy share neovascularization as a common etiology involving the pathological growth of retinal capillaries leading to blindness if left untreated. Current treatment modalities involve specialized injections into the eye that require not only outpatient visits to specialized treatment centers but are also associated with significant adverse effects. Orally bioavailable medications could revolutionize the treatment of retinopathies, by reducing adverse effects, sustaining vision, lowering the direct and indirect financial burden associated with these diseases, and increasing access to healthcare. Inspired by this idea, we have developed an approach that can be exploited to target essentially any therapeutic molecule to the eye. Our novel strategy of drug targeting will not only enrich the modified molecules in retinal tissue but will also reduce the therapeutic oral dose compared to existing anti-angiogenic therapy in cancer thereby increasing the safety of the treatment. This is achieved by absorbing a minute amount of the chemically and biologically stable molecules resulting in an extremely low plasma concentration and relying on a biological mechanism in the eye to activate the molecules to tether them to retinal target receptors and thereby extracting them from the blood. In the present application, we propose to demonstrate proof-of-concept of this strategy by modifying inhibitors of the vascular endothelial growth factor receptor (VEGFR). VEGFR is an endothelial receptor tyrosine kinase that is a key mediator of angiogenesis and an established drug target for the treatment of retinopathies. Our approach will elicit a paradigm shift in how we design future drug delivery strategies to the retina.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores